Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Ascendis Pharma A/S banner

Ascendis Pharma A/S
NASDAQ:ASND

Watchlist Manager
Ascendis Pharma A/S Logo
Ascendis Pharma A/S
NASDAQ:ASND
Watchlist
Price: 247.93 USD -0.57% Market Closed
Market Cap: $15.4B
Write Note Create Alert Ask AI

Wall St Price Targets

ASND Price Targets Summary
Ascendis Pharma A/S

Wall Street analysts forecast ASND stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ASND is 323.07 USD with a low forecast of 272.7 USD and a high forecast of 402.94 USD.

ASND Lowest Forecast
Wall Street Target
$272.7
10% Upside
ASND Average Forecast
Wall Street Target
$323.07
30% Upside
ASND Highest Forecast
Wall Street Target
$402.94
63% Upside
Lowest Forecast
Price Target
272.7 USD
10% Upside
Average Forecast
Price Target
323.07 USD
30% Upside
Highest Forecast
Price Target
402.94 USD
63% Upside
Ascendis Pharma A/S Competitors:
Price Targets
EBMT
Eagle Bancorp Montana Inc
11% Upside
HCAT
Health Catalyst Inc
17% Upside
SHLS
Shoals Technologies Group Inc
58% Upside
AMAL
Amalgamated Bank
12% Upside
EBMT
Eagle Bancorp Montana Inc
11% Upside
HCAT
Health Catalyst Inc
17% Upside
SHLS
Shoals Technologies Group Inc
58% Upside
AMAL
Amalgamated Bank
12% Upside

Revenue
Forecast

35% / Year
Past Growth
24% / Year
Estimated Growth
Estimates Accuracy
3%
Average Beat
35% / Year
Past Growth
24% / Year
Estimated Growth
Estimates Accuracy
3%
Average Beat

Over the last 12 years, the compound annual growth rate for Revenue has been 35%. The projected CAGR for the next 8 years is 24%.

What are analyst estimates?

Gross Profit
Forecast

N/A
Past Growth
25% / Year
Estimated Growth
Estimates Accuracy
0%
Average Beat
N/A
Past Growth
25% / Year
Estimated Growth
Estimates Accuracy
0%
Average Beat

The compound annual growth rate for Gross Profit over the next 8 years is 25%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat

What are analyst estimates?

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat

What are analyst estimates?

Continue ASND Research

Summary
ASND intrinsic value, competitors valuation, and company profile.
DCF Valuation
ASND stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ASND stock valuation using valuation multiples.
Wall St Estimates
ASND price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ASND stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Ascendis Pharma A/S listings:
F • EUR
A71
 SWB • EUR
A71
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is ASND's stock price target?
Price Target
323.07 USD

According to Wall Street analysts, the average 1-year price target for ASND is 323.07 USD with a low forecast of 272.7 USD and a high forecast of 402.94 USD.

What is the Revenue forecast for Ascendis Pharma A/S?
Projected CAGR
24%

Over the last 12 years, the compound annual growth rate for Revenue has been 35%. The projected CAGR for the next 8 years is 24%.

What is the Gross Profit forecast for Ascendis Pharma A/S?
Projected CAGR
25%

The compound annual growth rate for Gross Profit over the next 8 years is 25%.

Back to Top
ALPHA SPREAD
Follow us
Join 355,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett